Arbutus Biopharma (ABUS) Current Leases (2019 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Current Leases of $631000.0 for Q1 2026, up 12.08% year-on-year from $563000.0 in Q1 2025, and up 15.36% on a QoQ basis from $547000.0 in Q4 2025.
Arbutus Biopharma (ABUS) Current Leases (2019 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Current Leases for 8 consecutive years, with $631000.0 the latest figure, recorded in Q1 2026.
- Quarterly Current Leases rose 12.08% year-over-year to $631000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $631000.0 (up 12.08% YoY) and the FY2025 annual result came in at $547000.0, up 13.25% from the prior year.
- Current Leases improved to $631000.0 in Q1 2026 per ABUS's latest filing, from $547000.0 in the prior quarter.
- Over the last five years, Current Leases for ABUS reached as high as $631000.0 in Q1 2026 and fell as low as $360000.0 in Q3 2022.
- A 5-year average of $465882.4 and a median of $453000.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases declined 6.74% — and 2023, when it climbed 14.44%.
- Year by year, Current Leases stood at $372000.0 in 2022, then advanced by 14.25% to $425000.0 in 2023, then increased by 13.65% to $483000.0 in 2024, then advanced by 13.25% to $547000.0 in 2025, then advanced by 15.36% to $631000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $631000.0, $547000.0, and $531000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 631,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 631,000.00 |
| Dec 31, 2025 | 547,000.00 |
| Sep 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 514,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | 483,000.00 |
| Sep 30, 2024 | 468,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 502,000.00 |
| Dec 31, 2023 | 425,000.00 |
| Sep 30, 2023 | 412,000.00 |
| Jun 30, 2023 | 397,000.00 |
| Mar 31, 2023 | 446,000.00 |
| Dec 31, 2022 | 372,000.00 |
| Sep 30, 2022 | 360,000.00 |
| Jun 30, 2022 | 377,000.00 |
| Mar 31, 2022 | 439,000.00 |
| Dec 31, 2021 | 383,000.00 |
| Sep 30, 2021 | 386,000.00 |
| Jun 30, 2021 | 357,000.00 |